Abstract 1 in 8 women will be affected by breast cancer, which is the most diagnosed
malignancy among women. Although breast cancer was regarded as “immunologically …

Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple
negative breast cancer (TNBC), based on the phase III randomized controlled trial …

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of
cancer death in women worldwide. Despite the significant benefit of the use of conventional …

Background: Breast cancer has traditionally been considered to have a low immunogenic
potential compared to other tumor entities. Summary: The most extensively studied …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Breast cancer has historically been considered a non-immunogenic tumor. Multiple studies
over the last 10–15 years have demonstrated that a small subset of breast cancers is …

Highlights•The investigation of immunotherapeutic agents for breast cancer has shifted from
the metastatic to the early setting.•Different scenarios and designs exist for clinical trials …

Immunotherapy continues to redefine the solid tumor treatment landscape, with inhibitors of
the PD-L1/PD-1 immune checkpoint having the most widespread impact. As the most …

The recent demonstration of modest single-agent activity of programmed death-ligand 1 (PD-
L1) and programmed death receptor-1 (PD-1) antibodies in patients with breast cancer has …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …